Aptevo Therapeutics Inc. (APVO)
| Market Cap | 5.58M +79.9% |
| Revenue (ttm) | n/a |
| Net Income | -26.16M |
| EPS | -45.13 |
| Shares Out | 1.18M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 28,427 |
| Open | 5.030 |
| Previous Close | 5.080 |
| Day's Range | 4.710 - 5.030 |
| 52-Week Range | 3.800 - 235.978 |
| Beta | 1.69 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | May 13, 2026 |
About APVO
Aptevo Therapeutics Inc., a clinical-stage research and development biotechnology company, focuses on developing immunotherapeutic candidates for the treatment of various forms of cancer in the United States. The company develops its products using ADAPTIR and ADAPTIR-FLEX platforms to generate monospecific, bispecific, and multi-specific antibody candidates capable of enhancing the human immune system against cancer cells. Its lead clinical blood cancer candidate is mipletamig that is in Phase 1b/2 clinical trial for the treatment of acute mye... [Read more]
Financial Performance
Financial StatementsNews
Aptevo Therapeutics appoints Janatpour as SVP, CSO
Aptevo Therapeutics (APVO) announced the appointment of Mary Janatpour, Ph.D., as Senior Vice President, SVP, and Chief Scientific Officer, CSO. Dr. Janatpour brings more than 25 years of oncology res...
Aptevo Therapeutics Appoints Mary J. Janatpour, Ph.D.
Experienced oncology R&D leader appointed to support Aptevo's expanding oncology pipeline and new radiopharmaceutical development strategy SEATTLE, WA / ACCESS Newswire / May 28, 2026 / Aptevo Therape...
Aptevo, Niowave launch collab for radiopharmaceutical oncology programs
Aptevo Therapeutics (APVO) and Niowave announced a 50/50 strategic collaboration to develop up to three radiopharmaceutical oncology programs. Niowave made an at-the-market equity investment in Aptevo...
Aptevo and Niowave Launch Strategic Collaboration for Radiopharmaceutical Therapeutic Development, Includes Strategic Equity Investment by Niowave at Closing
50/50 Strategic Collaboration Will Develop Up to Three Radiopharmaceutical Programs Innovation and Investment Continue to Accelerate Across Radiopharmaceutical Oncology SEATTLE, WA AND LANSING, MI / A...
Aptevo Therapeutics reports Q1 cash and cash equivalents $14.5M
“Aptevo is entering a defining period as a company, supported by growing clinical momentum, a committed leadership team, and a pipeline with the potential to create significant long-term value,” said…
Aptevo Therapeutics Provides a 1Q26 Business Update; RAINIER on Track for 2026 Completion and Phase 2 Dose Selection
Mipletamig continues to perform, delivers 87% clinical benefit and 81% remission in frontline AML, with no CRS in frontline patients Executive leadership transition complete. Jeff Lamothe appointed CE...
Aptevo reports 87% clinical benefit in frontline AML patients in RAINIER trial
Aptevo Therapeutics (APVO) reported new clinical results from its RAINIER frontline acute myeloid leukemia trial. The company is on track to complete the Phase 1b dose-optimization trial and select th...
Aptevo Reports 87% Clinical Benefit and 81% Remission in 31 Evaluable Frontline AML Patients Through Cohort 5, Substantially Outperforming Benchmark; RAINIER on Track for 2026 Completion and Phase 2 Dose Selection
Program Enters Final Stage of Dose Optimization Data Continue to Demonstrate Strong Clinical Activity and Favorable Safety Across an Expanding Frontline Dataset SEATTLE, WA / ACCESS Newswire / May 6, ...
Aptevo Therapeutics reports FY25 EPS ($87.27) vs. ($31,460.23) last year
“2025 was a year of meaningful progress across our clinical programs, pipeline strategy and capital position,” said Marvin White, CEO. “Most importantly, recently reported mipletamig data continue to ...
Aptevo Therapeutics sees cash runway into 4Q26
Aptevo ended 2025 with $21.6 million in cash and cash equivalents, compared with $8.7 million at December 31, 2024, and expects current resources to support operations into the fourth quarter…
Aptevo Provides State of the Business Report and 2025 Financial Results
Latest mipletamig data delivers 86% clinical benefit rate with no cytokine release syndrome in 28 frontline AML patients, supporting its potential to enhance standard-of-care combination therapy Compa...
Aptevo to Participate in March 2026 Conferences
SEATTLE, WA / ACCESS Newswire / March 19, 2026 / Aptevo Therapeutics Inc. (NASDAQ:APVO), a clinical-stage biotechnology company developing novel immune-oncology therapeutics based on its proprietary A...
Aptevo Therapeutics announces interim data for mipletamig combination
Aptevo Therapeutics (APVO) announced new interim data for mipletamig in combination with venetoclax and azacitidine in newly diagnosed acute myeloid leukemia patients who are either elderly or unfit f...
Mipletamig Delivers Compelling 86% Clinical Benefit Rate and No CRS as Evaluable AML Patient Data increases by Nearly 50%
Frontline patient outcomes are making the case for mipletamig to enhance standard-of-care therapy alongside venetoclax + azacitidine SEATTLE, WA / ACCESS Newswire / March 10, 2026 / Aptevo Therapeutic...
Aptevo Therapeutics CEO Marvin White to retire, assume Executive Chair role
Aptevo Therapeutics (APVO) announced executive leadership transitions to support the Company’s continued execution, drive achievement of long-term strategic objectives, and next phase of growth. Effec...
Aptevo Announces Executive Leadership Transitions to Support Next Phase of Growth
Clinical progress, pipeline expansion, and operational momentum underpin leadership continuity as the Company advances into 2026 and beyond SEATTLE, WA / ACCESS Newswire / February 3, 2026 / Aptevo Th...
Aptevo Therapeutics files to sell 7.075M shares of common stock for holders
16:08 EST Aptevo Therapeutics (APVO) files to sell 7.075M shares of common stock for holders
Aptevo Therapeutics secures $60M equity line of credit
Aptevo Therapeutics (APVO) entered into a $60M equity line of credit agreement with Yorkville Advisors Global, LP, strengthening the Company’s financial flexibility as it continues to advance its clin...
Aptevo Therapeutics Secures $60 Million Equity Line of Credit to Support Multispecific Portfolio Advancement, Increase Strategic Optionality
Together with cash on hand, the fully leveraged facility extends Aptevo's funding runway into 2029, enabling achievement of key clinical and preclinical milestones SEATTLE, WA / ACCESS Newswire / Janu...
Aptevo Therapeutics trading halted, news pending
19:50 EST Aptevo Therapeutics (APVO) trading halted, news pending
Aptevo Therapeutics Announces 1-for-18 Reverse Stock Split
SEATTLE, WA / ACCESS Newswire / December 26, 2025 / Aptevo Therapeutics Inc. (NASDAQ:APVO), a clinical-stage biotechnology company focused on developing novel immune-oncology therapeutics based on its...
Aptevo Therapeutics presents preliminary results from Phase 1b/2 RAINIER study
Aptevo Therapeutics (APVO) presented preliminary results from its ongoing Phase 1b/2 RAINIER study evaluating mipletamig, a CD123 x CD3 bispecific molecule, in combination with azacitidine and venetoc...
Aptevo Therapeutics Highlights Compelling Safety and Strong Remission Rates for Mipletamig in Frontline AML at ASH 2025
100% of patients in Cohorts 1-3 remain free of cytokine release syndrome CRIS-7-derived CD3 design underpins a controlled T-cell response, supporting the differentiated safety profile, combinability w...
Aptevo Therapeutics debuts trispecific antibody candidate APVO451
Aptevo Therapeutics (APVO) announced the first presentation of preclinical data for its new trispecific antibody, APVO451, at the Society for Immunotherapy of Cancer Annual Meeting on Saturday, Novemb...
Aptevo Debuts First Trispecific Antibody Candidate, APVO451, with Preclinical Data Demonstrating Immune Activation in Hard-to-Treat Solid Tumors
First data on Aptevo's new molecule presented at the Society for Immunotherapy of Cancer (SITC) Annual Meeting SEATTLE, WASHINGTON / ACCESS Newswire / November 10, 2025 / Aptevo Therapeutics ("Aptevo"...